| Variable . | Placebo (n = 39) . | rhPTH(1-84) (n = 83) . | P Valuea . |
|---|---|---|---|
| Age, mean (SD), y | 49.5 (13.3) | 46.6 (12.3) | |
| Female | 32 (82.1) | 64 (77.1) | 0.639 |
| Body mass index, mean (SD), kg/m2 | 28.9 (5.4) | 29.1 (6.1) | |
| Duration of hypoparathyroidism, y | |||
| Mean (SD) | 11.8 (8.1) | 14.6 (11.2) | |
| ≤5 | 9 (23.1) | 15 (18.1) | |
| >5–10 | 13 (33.3) | 27 (32.5) | |
| >10 | 17 (43.6) | 41 (49.4) | |
| Postsurgical etiology | 28 (71.8) | 59 (71.1) | 1.000 |
| Prescribed calcium dose at baseline, mg/d | |||
| Mean (SD) | 1932 (892.0) | 2185 (1477.3) | |
| 0−2000 | 29 (74.4) | 56 (67.5) | |
| >2000 | 10 (25.6) | 27 (32.5) | |
| Prescribed vitamin D dose at baseline, µg/db | |||
| Mean (SD) | 1.1 (0.7) | 1.1 (0.9) | |
| Low dose | 3 (7.7) | 6 (7.2) | |
| Medium dose | 12 (30.8) | 21 (25.3) | |
| High dose | 24 (61.5) | 56 (67.5) | |
| Albumin-corrected serum calcium at baseline, mean (SD), mg/dL | 8.6 (0.6) | 8.5 (0.8) | |
| Parathyroid hormone at baseline, mean (SD), ng/Lc | 6.5 (6.5) | 6.3 (8.7) |
| Variable . | Placebo (n = 39) . | rhPTH(1-84) (n = 83) . | P Valuea . |
|---|---|---|---|
| Age, mean (SD), y | 49.5 (13.3) | 46.6 (12.3) | |
| Female | 32 (82.1) | 64 (77.1) | 0.639 |
| Body mass index, mean (SD), kg/m2 | 28.9 (5.4) | 29.1 (6.1) | |
| Duration of hypoparathyroidism, y | |||
| Mean (SD) | 11.8 (8.1) | 14.6 (11.2) | |
| ≤5 | 9 (23.1) | 15 (18.1) | |
| >5–10 | 13 (33.3) | 27 (32.5) | |
| >10 | 17 (43.6) | 41 (49.4) | |
| Postsurgical etiology | 28 (71.8) | 59 (71.1) | 1.000 |
| Prescribed calcium dose at baseline, mg/d | |||
| Mean (SD) | 1932 (892.0) | 2185 (1477.3) | |
| 0−2000 | 29 (74.4) | 56 (67.5) | |
| >2000 | 10 (25.6) | 27 (32.5) | |
| Prescribed vitamin D dose at baseline, µg/db | |||
| Mean (SD) | 1.1 (0.7) | 1.1 (0.9) | |
| Low dose | 3 (7.7) | 6 (7.2) | |
| Medium dose | 12 (30.8) | 21 (25.3) | |
| High dose | 24 (61.5) | 56 (67.5) | |
| Albumin-corrected serum calcium at baseline, mean (SD), mg/dL | 8.6 (0.6) | 8.5 (0.8) | |
| Parathyroid hormone at baseline, mean (SD), ng/Lc | 6.5 (6.5) | 6.3 (8.7) |
Data given as no. (%) unless otherwise indicated.
Calculated based on t tests, except for the variables of female sex and etiology, which were based on the Fisher exact test.
For calcitriol, low dose is ≤0.25 µg/d; medium dose, >0.25−0.5 µg/d; and high dose, >0.5 µg/d. For alfacalcidol, low dose is <0.50 µg/d; medium dose, >0.5−1.0 µg/d; and high dose, is >1.0 µg/d.
Normal range in adults is 14−72 ng/L.
| Variable . | Placebo (n = 39) . | rhPTH(1-84) (n = 83) . | P Valuea . |
|---|---|---|---|
| Age, mean (SD), y | 49.5 (13.3) | 46.6 (12.3) | |
| Female | 32 (82.1) | 64 (77.1) | 0.639 |
| Body mass index, mean (SD), kg/m2 | 28.9 (5.4) | 29.1 (6.1) | |
| Duration of hypoparathyroidism, y | |||
| Mean (SD) | 11.8 (8.1) | 14.6 (11.2) | |
| ≤5 | 9 (23.1) | 15 (18.1) | |
| >5–10 | 13 (33.3) | 27 (32.5) | |
| >10 | 17 (43.6) | 41 (49.4) | |
| Postsurgical etiology | 28 (71.8) | 59 (71.1) | 1.000 |
| Prescribed calcium dose at baseline, mg/d | |||
| Mean (SD) | 1932 (892.0) | 2185 (1477.3) | |
| 0−2000 | 29 (74.4) | 56 (67.5) | |
| >2000 | 10 (25.6) | 27 (32.5) | |
| Prescribed vitamin D dose at baseline, µg/db | |||
| Mean (SD) | 1.1 (0.7) | 1.1 (0.9) | |
| Low dose | 3 (7.7) | 6 (7.2) | |
| Medium dose | 12 (30.8) | 21 (25.3) | |
| High dose | 24 (61.5) | 56 (67.5) | |
| Albumin-corrected serum calcium at baseline, mean (SD), mg/dL | 8.6 (0.6) | 8.5 (0.8) | |
| Parathyroid hormone at baseline, mean (SD), ng/Lc | 6.5 (6.5) | 6.3 (8.7) |
| Variable . | Placebo (n = 39) . | rhPTH(1-84) (n = 83) . | P Valuea . |
|---|---|---|---|
| Age, mean (SD), y | 49.5 (13.3) | 46.6 (12.3) | |
| Female | 32 (82.1) | 64 (77.1) | 0.639 |
| Body mass index, mean (SD), kg/m2 | 28.9 (5.4) | 29.1 (6.1) | |
| Duration of hypoparathyroidism, y | |||
| Mean (SD) | 11.8 (8.1) | 14.6 (11.2) | |
| ≤5 | 9 (23.1) | 15 (18.1) | |
| >5–10 | 13 (33.3) | 27 (32.5) | |
| >10 | 17 (43.6) | 41 (49.4) | |
| Postsurgical etiology | 28 (71.8) | 59 (71.1) | 1.000 |
| Prescribed calcium dose at baseline, mg/d | |||
| Mean (SD) | 1932 (892.0) | 2185 (1477.3) | |
| 0−2000 | 29 (74.4) | 56 (67.5) | |
| >2000 | 10 (25.6) | 27 (32.5) | |
| Prescribed vitamin D dose at baseline, µg/db | |||
| Mean (SD) | 1.1 (0.7) | 1.1 (0.9) | |
| Low dose | 3 (7.7) | 6 (7.2) | |
| Medium dose | 12 (30.8) | 21 (25.3) | |
| High dose | 24 (61.5) | 56 (67.5) | |
| Albumin-corrected serum calcium at baseline, mean (SD), mg/dL | 8.6 (0.6) | 8.5 (0.8) | |
| Parathyroid hormone at baseline, mean (SD), ng/Lc | 6.5 (6.5) | 6.3 (8.7) |
Data given as no. (%) unless otherwise indicated.
Calculated based on t tests, except for the variables of female sex and etiology, which were based on the Fisher exact test.
For calcitriol, low dose is ≤0.25 µg/d; medium dose, >0.25−0.5 µg/d; and high dose, >0.5 µg/d. For alfacalcidol, low dose is <0.50 µg/d; medium dose, >0.5−1.0 µg/d; and high dose, is >1.0 µg/d.
Normal range in adults is 14−72 ng/L.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
